Drug intelligence / Profile preview

VT500X

Development stage: Preclinical
Lead developer: Vigeo Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

VT500X is a preclinical-stage monoclonal antibody developed by Vigeo Therapeutics for the treatment of various cancers. It specifically targets Serine protease 2 (PRSS2), also known as Trypsin-2. PRSS2 is a serine protease that is often overexpressed in the tumor microenvironment, where it contributes to tumor progression, extracellular matrix remodeling, and metastasis. By inhibiting PRSS2, VT500X aims to disrupt these pro-tumorigenic pathways. It is being developed as part of Vigeo's oncology pipeline, often appearing alongside VT400X.

Targets

PRSS2 (Trypsin-2)

Beyond the preview

Go deeper on VT500X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VT500X.

Explore the full profile